OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3944 participants.
Also called NCT05418556
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,944 participants
- Sponsor
- Registry
-
NCT05418556
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT05418556. Randomized; no masking; primary purpose treatment. Start 2022-10-21 (actual); primary completion 2027-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation
- Acronym
- OPTIMIZE-APT
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- aspirin
- Lead sponsor
- Asan Medical Center
Record details
- Record id
cardio:ct-nct05418556- Content hash
21278e62280ca211212633d4a292428631ba11fe31d773499114e1f8def825ed